Artal Group Sa Decreased Acceleron Pharma Inc (Call) (NASDAQ:XLRN) Stake By $36.00 Million

August 13, 2018 - By Jason Dias

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It increased, as 13 investors sold XLRN shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. Invesco owns 5,611 shares. Brown Advisory Incorporated has invested 0.05% in Acceleron Pharma Inc. (NASDAQ:XLRN). First Manhattan holds 155,600 shares or 0.03% of its portfolio. Great Point Ltd Liability Company holds 462,245 shares or 0% of its portfolio. Principal Group holds 0.01% or 135,491 shares. 166 were reported by Riverhead Capital Ltd Llc. Tekla Capital Mgmt Ltd Liability Co reported 273,098 shares stake. Metropolitan Life Insur Co New York accumulated 12,234 shares. Lord Abbett Co Limited Liability Corporation, a New Jersey-based fund reported 116,514 shares. Td Asset reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Federated Invsts Pa owns 134,893 shares. Putnam Ltd Liability Corp reported 28,588 shares stake. Natl Bank Of Ny Mellon Corporation invested 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Polar Cap Llp stated it has 0.42% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Morgan Stanley holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 122,224 shares.

Since March 6, 2018, it had 0 buys, and 7 insider sales for $3.31 million activity. MCLAUGHLIN KEVIN F had sold 25,000 shares worth $1.20 million. 1,204 shares were sold by Quisel John D, worth $46,232. $46,205 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Kumar Ravindra. The insider POPS RICHARD F sold 37,500 shares worth $1.55M. Sherman Matthew L sold $176,772 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3.

Artal Group Sa decreased its stake in Acceleron Pharma Inc (Call) (NASDAQ:XLRN) by 88.24% based on its latest 2018Q2 regulatory filing with the SEC. Artal Group Sa sold 750,000 shares as the company’s stock declined 18.55% with the market. The institutional investor held 100,000 shares of the biological products (no diagnostic substances) company at the end of 2018Q2, valued at $4.85M, down from 850,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc (Call) for a number of months, seems to be less bullish one the $2.19 billion market cap company. The stock increased 2.22% or $1.03 during the last trading session, reaching $47.5. About 255,178 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since August 13, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 9 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Acceleron Pharma had 10 analyst reports since February 26, 2018 according to SRatingsIntel. As per Tuesday, May 22, the company rating was initiated by Oppenheimer. The firm earned “Outperform” rating on Friday, June 29 by Credit Suisse. As per Monday, February 26, the company rating was upgraded by JP Morgan. Citigroup maintained the shares of XLRN in report on Thursday, March 1 with “Buy” rating. The stock has “Overweight” rating by Barclays Capital on Wednesday, February 28. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, February 28. The firm earned “Neutral” rating on Friday, June 29 by Goldman Sachs. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Buy” rating given on Wednesday, March 28 by H.C. Wainwright. Morgan Stanley downgraded the shares of XLRN in report on Friday, July 13 to “Equal-Weight” rating. The firm has “Neutral” rating by PiperJaffray given on Tuesday, July 10.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company has market cap of $2.19 billion. The Company’s therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. It currently has negative earnings. The firm is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Benzinga.com which released: “Acceleron Pharma Q2 Earnings Preview” on August 02, 2018, also Businesswire.com with their article: “Acceleron Reports Second Quarter 2018 Operating and Financial Results” published on August 02, 2018, Fool.com published: “Did This Top Biotech Stock Just Go on Sale?” on July 25, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” published on July 28, 2018 as well as Fool.com‘s news article titled: “Here’s Why Acceleron Pharma Inc. Lost 10.2% in July” with publication date: August 04, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.